Cargando…

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition

Deregulated Polycomb repressive complex 2 (PRC2) is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy. Disrupting the EZH2–EED interaction, which is required for PRC2 enzymatic activity, is a promising strategy for cancer treatment. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Kai-li, Shen, Qian-qian, Fang, Yan-fen, Sun, Yi-ming, Ding, Jian, Chen, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468275/ https://www.ncbi.nlm.nih.gov/pubmed/31171828 http://dx.doi.org/10.1038/s41401-019-0248-2

Ejemplares similares

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2020)

AZD9291-induced Acute Interstitial Lung Disease
por: Nie, Ke-Ke, et al.
Publicado: (2016)

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
por: Chen, Tianxiang, et al.
Publicado: (2019)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

AZD9291-resistant non-small cell lung cancer cell-derived exosomal lnc-MZT2A-5:1 induces the activation of fibroblasts
por: Song, Liwei, et al.
Publicado: (2021)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
por: Li, Wen, et al.
Publicado: (2021)

Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia
por: Ntziachristos, Panagiotis, et al.
Publicado: (2012)

Conversion of random X-inactivation to imprinted X-inactivation by maternal PRC2
por: Harris, Clair, et al.
Publicado: (2019)

Structure and Function of the Polycomb Repressive Complexes PRC1 and PRC2
por: Angrand, Pierre-Olivier
Publicado: (2022)

Variant PCGF1-PRC1 links PRC2 recruitment with differentiation-associated transcriptional inactivation at target genes
por: Sugishita, Hiroki, et al.
Publicado: (2021)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis
por: Su, Dongxue, et al.
Publicado: (2021)

Cooperative DNA looping by PRC2 complexes
por: Lin, Xingcheng, et al.
Publicado: (2021)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

AZD-1222: Immune complex-mediated glomerulonephritis: case report
Publicado: (2022)

Jarid2 binds mono-ubiquitylated H2A lysine 119 to mediate crosstalk between Polycomb complexes PRC1 and PRC2
por: Cooper, Sarah, et al.
Publicado: (2016)

Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes
por: Zhen, Chao Yu, et al.
Publicado: (2014)

Polycomb-like proteins link the PRC2 complex to CpG islands
por: Li, Haojie, et al.
Publicado: (2017)

Synergy between Variant PRC1 Complexes Defines Polycomb-Mediated Gene Repression
por: Fursova, Nadezda A., et al.
Publicado: (2019)

BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation
por: Campagne, Antoine, et al.
Publicado: (2019)

Mammalian PRC1 Complexes: Compositional Complexity and Diverse Molecular Mechanisms
por: Geng, Zhuangzhuang, et al.
Publicado: (2020)

RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3
por: Tavares, Lígia, et al.
Publicado: (2012)

RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3
por: Tavares, Lígia, et al.
Publicado: (2012)

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses
por: Yan, Juan, et al.
Publicado: (2022)

Interdependence of PRC1 and PRC2 for recruitment to Polycomb Response Elements
por: Kahn, Tatyana G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vkn838j4f3t0lptfbhme0b2590